Aptamer modified Zr-based porphyrinic nanoscale metal-organic frameworks for active-targeted chemo-photodynamic therapy of tumors



Feng, Haidi, Zhao, Lu, Bai, Zhiqiang, Xin, Zhihui, Wang, Chaoyu, Liu, Lizhen, Song, Jinping, Zhang, Haifei, Bai, Yunfeng and Feng, Feng
(2023) Aptamer modified Zr-based porphyrinic nanoscale metal-organic frameworks for active-targeted chemo-photodynamic therapy of tumors. RSC ADVANCES, 13 (16). pp. 11215-11224.

[thumbnail of d3ra00753g.pdf] PDF
d3ra00753g.pdf - Open Access published version

Download (1MB) | Preview

Abstract

Active-targeted nanoplatforms could specifically target tumors compared to normal cells, making them a promising therapeutic agent. The aptamer is a kind of short DNA or RNA sequence that can specifically bind to target molecules, and could be widely used as the active targeting agents of nanoplatforms to achieve active-targeted therapy of tumors. Herein, an aptamer modified nanoplatform DOX@PCN@Apt-M was designed for active-targeted chemo-photodynamic therapy of tumors. Zr-based porphyrinic nanoscale metal organic framework PCN-224 was synthesized through a one-pot reaction, which could produce cytotoxic <sup>1</sup>O<sub>2</sub> for efficient treatment of tumor cells. To improve the therapeutic effect of the tumor, the anticancer drug doxorubicin (DOX) was loaded into PCN-224 to form DOX@PCN-224 for tumor combination therapy. Active-targeted combination therapy achieved by modifying the MUC1 aptamer (Apt-M) onto DOX@PCN-224 surface can not only further reduce the dosage of therapeutic agents, but also reduce their toxic and side effects on normal tissues. <i>In vitro</i>, experimental results indicated that DOX@PCN@Apt-M exhibited enhanced combined therapeutic effect and active targeting efficiency under 808 nm laser irradiation for MCF-7 tumor cells. Based on PCN-224 nanocarriers and aptamer MUC1, this work provides a novel strategy for precisely targeting MCF-7 tumor cells.

Item Type: Article
Uncontrolled Keywords: 34 Chemical Sciences, Biotechnology, Orphan Drug, Bioengineering, Nanotechnology, Rare Diseases, Cancer, 5 Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals
Divisions: Faculty of Science and Engineering > School of Physical Sciences
Depositing User: Symplectic Admin
Date Deposited: 21 Apr 2023 08:22
Last Modified: 05 Jul 2024 06:25
DOI: 10.1039/d3ra00753g
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3169818